{
    "nctId": "NCT00237133",
    "briefTitle": "Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women",
    "officialTitle": "PREDICT TRIAL- Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR)",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 112,
    "primaryOutcomeMeasure": "Safety and tolerability of Letrozole",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Postmenopausal women\n2. Primary locally invasive breast cancer\n3. Histological confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone (PgR) positive, defined by core biopsy immunohistochemistry with \\> 10% positive malignant epithelial cells.\n4. Post menopausal status\n5. Tumor measurable by clinical examination, mammography and ultrasound\n\nExclusion Criteria:\n\n1. Prior treatment with letrozole or tamoxifen.\n2. Patients with bilateral breast tumors\n3. Patients who are eligible for breast conserving surgery\n4. Evidence of inflammatory breast cancer or distant metastasis.\n5. Other concurrent malignant disease\n6. Concomitant anti-cancer treatments such as chemotherapy\n\nOther protocol-defined exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}